The Role of PARPi in Prostate Cancer:

Experts Knowledge Share

On August 26th and August 28th 2020, two “Experts Knowledge Share” interactive webinars connected global participants with renowned panel experts to discuss the therapeutic role of PARP inhibitors in prostate cancer. Panellists included Dr. Neal D. Shore (Programme Chair; Carolina Urologic Research Center), Prof. Andrew J. Armstrong (Duke University School of Medicine), and Prof. Emmanuel S. Antonarakis (Johns Hopkins Medicine).

Key topics included:

  • Prevalence of DDR mutations in prostate cancer, and somatic and germline testing
  • PARPi mechanism of action
  • Recent clinical trial data and ongoing studies
  • Efficacy and safety profiles of PARPi
  • Patient case studies

In this video, Dr. Neal D. Shore (Carolina Urologic Research Center) summarises this Experts Knowledge Share programme and the expanding role for PARP inhibitors in prostate cancer therapy.


Share feedback

The views expressed in this video are that of the expert and do not necessarily represent the views of the expert’s academic institution, employer, organisation, or other group or individual. AstraZeneca has provided a sponsorship grant towards this independent programme.